Hepatitis B antiviral agents

• US 10,189,846 B2
• Filed: 06/08/2017
• Issued: 01/29/2019
• Est. Priority Date: 06/10/2016
• Status: Active Grant

• Current Assignee: Enanta Pharmaceuticals Incorporated
• Original Assignee: Enanta Pharmaceuticals Incorporated
• Inventors: Qiu, Yao-Ling, Cao, Hui, Peng, Xiaowen, Li, Wei, Kass, Jorden, Gao, Xuri, Jin, Meizhong, Or, Yat Sun
• Primary Examiner(s): Murray, Jeffrey H
• Application Number:
  US15/617,445
• Publication Number:
  US 20170355701A1
• Time in Patent Office: 600 Days
• Field of Search: 5142591, 544282
• CPC Class Codes: A61K 31/519 ortho- or peri-condensed with heterocyclic rings
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 31/20 for DNA viruses
• CPC Class Codes: C07D 487/04 Ortho-condensed systems

Abstract

The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, thereof:

which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Claims

1. A compound represented by Formula (I):

2. The compound of claim 1, wherein A is selected from the following by removal of one hydrogen atom:

3. The compound of claim 1, wherein Y is selected from the following:

4. The compound of claim 1, represented by Formula (IIa-1), or a pharmaceutically acceptable salt thereof,

5. The compound of claim 1, represented by Formula (IIIa), or a pharmaceutically acceptable salt thereof,

6. The compound of claim 5, represented by Formula (IIIa) or (IIIb), or a pharmaceutically acceptable salt thereof, wherein

7. The compound of claim 1, selected from the compounds set forth below or a pharmaceutically acceptable salt thereof:

8. A pharmaceutical composition, comprising a compound according to claim 1 or a pharmaceutically acceptable salt thereof, in combination with a pharmaceutically acceptable carrier or excipient.